Eli Lilly and Company (LLY)vsXeris Pharmaceuticals Inc (XERS)
LLY
Eli Lilly and Company
$1,102.08
+0.90%
HEALTHCARE · Cap: $1.01T
XERS
Xeris Pharmaceuticals Inc
$6.90
+0.49%
HEALTHCARE · Cap: $1.17B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 22847% more annual revenue ($72.25B vs $314.85M). LLY leads profitability with a 35.0% profit margin vs 3.8%. LLY trades at a lower P/E of 40.2x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
XERS
Hold36
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 38.3% year-over-year
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
3.8% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : XERS
The strongest argument for XERS centers on Revenue Growth. Revenue growth of 38.3% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : XERS
The primary concerns for XERS are EPS Growth, Market Cap, Profit Margin. A P/E of 97.0x leaves little room for execution misses. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while XERS is a hypergrowth play — different risk/reward profiles.
XERS carries more volatility with a beta of 0.90 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 36/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Xeris Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?